New England Journal of Medicine

دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه

ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
~~قیمت : 3,800,000 تومان~~
قیمت ویژه : 1,900,000تومان

سفارش

Emerging Infectious Diseases — Learning from the Past and Looking to the Future

Christopher Elias, M.D., M.P.H., John N. Nkengasong, Ph.D., and Firdausi Qadri, Ph.D.

doi : 10.1056/NEJMp2034517

N Engl J Med 2021; 384:1181-1184

خرید پکیج و مشاهده آنلاین مقاله

Ensuring That LGBTQI+ People Count — Collecting Data on Sexual Orientation, Gender Identity, and Intersex Status

Kellan E. Baker, Ph.D., M.P.H., Carl G. Streed, Jr., M.D., M.P.H., and Laura E. Durso, Ph.D.

doi : 10.1056/NEJMp2032447

N Engl J Med 2021; 384:1184-1186

خرید پکیج و مشاهده آنلاین مقاله

“To Mitigate the Afflictions of the Human Race” — The Legacy of Dr. Rebecca Crumpler

Perri Klass, M.D.

doi : 10.1056/NEJMp2032451

N Engl J Med 2021; 384:1186-1189

خرید پکیج و مشاهده آنلاین مقاله

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly, M.B., B.Ch., M.B.A., Jaffer A. Ajani, M.D., Jaroslaw Kuzdzal, M.D., Ph.D., Thomas Zander, M.D., Eric Van Cutsem, M.D., Ph.D., Guillaume Piessen, M.D., Ph.D., Guillermo Mendez, M.D., Josephine Feliciano, M.D., Satoru Motoyama, M.D., Ph.D., Astrid Lièvre, M.D., Ph.D., Hope Uronis, M.D., Elena Elimova, M.D., Cecile Grootscholten, M.D., Ph.D., Karen Geboes, M.D., Ph.D., Syed Zafar, M.D., Stephanie Snow, M.D., Andrew H. Ko, M.D., Kynan Feeney, M.D., Michael Schenker, M.D., Ph.D., Piotr Kocon, M.D., Ph.D., Jenny Zhang, M.D., Ph.D., Lili Zhu, Ph.D., Ming Lei, Ph.D., Prianka Singh, Pharm.D., M.P.H., Kaoru Kondo, M.Sc., James M. Cleary, M.D., Ph.D., and Markus Moehler, M.D., Ph.D. for the CheckMate 577 Investigators*

doi : 10.1056/NEJMoa2032125

N Engl J Med 2021; 384:1191-1203

No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.

خرید پکیج و مشاهده آنلاین مقاله

Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Marc Humbert, M.D., Ph.D., Vallerie McLaughlin, M.D., J. Simon R. Gibbs, M.D., Mardi Gomberg-Maitland, M.D., Marius M. Hoeper, M.D., Ioana R. Preston, M.D., Rogerio Souza, M.D., Ph.D., Aaron Waxman, M.D., Ph.D., Pilar Escribano Subias, M.D., Ph.D., Jeremy Feldman, M.D., Gisela Meyer, M.D., David Montani, M.D., Ph.D., Karen M. Olsson, M.D., Solaiappan Manimaran, Ph.D., Jennifer Barnes, Ph.D., Peter G. Linde, M.D., Janethe de Oliveira Pena, M.D., Ph.D., and David B. Badesch, M.D. for the PULSAR Trial Investigators*

doi : 10.1056/NEJMoa2024277

N Engl J Med 2021; 384:1204-1215

Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is associated with both hereditary and idiopathic subtypes. Sotatercept, a novel fusion protein, binds activins and growth differentiation factors in the attempt to restore balance between growth-promoting and growth-inhibiting signaling pathways.

خرید پکیج و مشاهده آنلاین مقاله

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Sander F. Garrelfs, M.D., Yaacov Frishberg, M.D., Sally A. Hulton, M.D., Michael J. Koren, M.D., William D. O’Riordan, M.D., Pierre Cochat, M.D., Ph.D., Georges Deschênes, M.D., Ph.D., Hadas Shasha-Lavsky, M.D., Jeffrey M. Saland, M.D., William G. van’t Hoff, M.D., Daniel G. Fuster, M.D., Daniella Magen, M.D., Shabbir H. Moochhala, M.B., Ch.B., Ph.D., Gesa Schalk, M.D., Eva Simkova, M.D., Jaap W. Groothoff, M.D., Ph.D., David J. Sas, D.O., Kristin A. Meliambro, M.D., Jiandong Lu, Ph.D., Marianne T. Sweetser, M.D., Ph.D., Pushkal P. Garg, M.D., Akshay K. Vaishnaw, M.D., Ph.D., John M. Gansner, M.D., Ph.D., Tracy L. McGregor, M.D., and John C. Lieske, M.D. for the ILLUMINATE-A Collaborators*

doi : 10.1056/NEJMoa2021712

N Engl J Med 2021; 384:1216-1226

Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase.

خرید پکیج و مشاهده آنلاین مقاله

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

Iain B. McInnes, F.R.C.P., Jaclyn K. Anderson, D.O., Marina Magrey, M.D., Joseph F. Merola, M.D., Yi Liu, M.D., Mitsumasa Kishimoto, M.D., Slawomir Jeka, M.D., Cesar Pacheco-Tena, M.D., Ph.D., Xin Wang, Ph.D., Liang Chen, M.S., Patrick Zueger, Pharm.D., Ph.D., John Liu, M.D., Aileen L. Pangan, M.D., and Frank Behrens, M.D.

doi : 10.1056/NEJMoa2022516

N Engl J Med 2021; 384:1227-1239

The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor ? inhibitor, in patients who have an inadequate response to nonbiologic disease-modifying antirheumatic drugs are unclear.

خرید پکیج و مشاهده آنلاین مقاله

Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease

Placide Mbala-Kingebeni, M.D., Ph.D., Catherine Pratt, M.Sc., Mbusa Mutafali-Ruffin, M.D., Matthias G. Pauthner, Ph.D., Faustin Bile, M.D., Antoine Nkuba-Ndaye, M.D., Allison Black, Ph.D., Eddy Kinganda-Lusamaki, M.D., Martin Faye, Ph.D., Amuri Aziza, M.Sc., Moussa M. Diagne, Ph.D., Daniel Mukadi, M.D., Bailey White, B.Sc., James Hadfield, Ph.D., Karthik Gangavarapu, B.Pharm., Nella Bisento, M.Sc., Donatien Kazadi, M.D., Bibiche Nsunda, B.Sc., Marceline Akonga, B.Sc., Olivier Tshiani, M.D., John Misasi, M.D., Aurelie Ploquin, Ph.D., Victor Epaso, M.D., Emilia Sana-Paka, M.D., Yannick Tutu Tshia N’kasar, M.D., Fabrice Mambu, M.D., Francois Edidi, M.D., Meris Matondo, M.D., Junior Bula Bula, M.D., Boubacar Diallo, M.D., Mory Keita, M.D., Marie R.D. Belizaire, M.D., Ibrahima S. Fall, Ph.D., Abdoulaye Yam, M.D., Sabue Mulangu, M.D., Anne W. Rimion, Ph.D., M.P.H., Elias Salfati, Ph.D., Ali Torkamani, Ph.D., Marc A. Suchard, M.D., Ph.D., Ian Crozier, M.D., Lisa Hensley, Ph.D., Andrew Rambaut, Ph.D., Ousmane Faye, Ph.D., Amadou Sall, Ph.D., Nancy J. Sullivan, Ph.D., Trevor Bedford, Ph.D., Kristian G. Andersen, Ph.D., Michael R. Wiley, Ph.D., Steve Ahuka-Mundeke, M.D., Ph.D., and Jean-Jacques Muyembe Tamfum, M.D., Ph.D.

doi : 10.1056/NEJMoa2024670

N Engl J Med 2021; 384:1240-1247

During the 2018–2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus–based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)–specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.)

خرید پکیج و مشاهده آنلاین مقاله